Back to top
more

Catalent (CTLT)

(Real Time Quote from BATS)

$58.50 USD

58.50
284,255

+0.10 (0.17%)

Updated Jul 25, 2024 10:30 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

5-Strong Sell of 5         5

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth C Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 41% (103 out of 250)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

UTHR vs. CTLT: Which Stock Is the Better Value Option?

UTHR vs. CTLT: Which Stock Is the Better Value Option?

Catalent (CTLT) Expands Its Facility Capabilities in Germany

Catalent's (CTLT) latest capability expansion is expected to boost its business in the global clinical trials space in its Clinical Development & Supply network.

UTHR vs. CTLT: Which Stock Should Value Investors Buy Now?

UTHR vs. CTLT: Which Stock Is the Better Value Option?

UTHR or CTLT: Which Is the Better Value Stock Right Now?

UTHR vs. CTLT: Which Stock Is the Better Value Option?

Why Is Catalent (CTLT) Up 0.4% Since Last Earnings Report?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Catalent's (CTLT) Latest Partnership to Boost Clinical Trials

Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.

Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up

Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.

Catalent (CTLT) Reports Q3 Loss, Misses Revenue Estimates

Catalent (CTLT) delivered earnings and revenue surprises of -125% and 3.10%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Should You Invest in Novo Nordisk (NVO) Ahead of Q1 Earnings?

Novo Nordisk's (NVO) revenues in the first quarter of 2024 are expected to have been driven by its diabetes and obesity care product sales, especially Ozempic, Rybelsus and Wegovy.

TAK or CTLT: Which Is the Better Value Stock Right Now?

TAK vs. CTLT: Which Stock Is the Better Value Option?

Charles River (CRL) Forges Collaboration With Ship of Theseus

Charles River (CRL) is set to perform plasmid production for Ship of Theseus.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

Smart Beta ETF report for RSPH

Catalent (CTLT) Q2 Earnings Lag Estimates, Gross Margin Down

Catalent (CTLT) reports lower revenues in Biologics segments in its second-quarter fiscal 2024, resulting in overall soft performance.

Catalent (CTLT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Although the revenue and EPS for Catalent (CTLT) give a sense of how its business performed in the quarter ended December 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Catalent (CTLT) Rides on Acquisition Offer From Novo Holdings

Catalent (CTLT) inks a merger agreement with Novo Holdings, under which the latter will acquire Catalent for $16.5 billion.

Catalent (CTLT) to Report Q2 Earnings: What's in the Cards?

Catalent's (CTLT) fiscal second-quarter results are likely to be driven by its non-COVID non-Sarepta Biologics business.

Strength Seen in Catalent (CTLT): Can Its 9.7% Jump Turn into More Strength?

Catalent (CTLT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Novo Nordisk (NVO) to Acquire 3 Catalent Sites for $11B

Novo Nordisk (NVO) will acquire Catalent's three manufacturing sites from Novo Holdings to expand its manufacturing capacity.

Is Invesco S&P 500 Equal Weight Health Care ETF (RSPH) a Strong ETF Right Now?

Smart Beta ETF report for RSPH

Stock Market News for Jan 8, 2024

Wall Street closed higher after a choppy session on Friday to finish the first week of 2024.

Recursion Pharmaceuticals (RXRX) Soars 7.4%: Is Further Upside Left in the Stock?

Recursion Pharmaceuticals (RXRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Catalent (CTLT) Up 4.1% Since Last Earnings Report: Can It Continue?

Catalent (CTLT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Retain Catalent (CTLT) Stock for Now

Catalent's (CTLT) products and services portfolio and technology foundation raise optimism about the stock.

Is SPDR S&P Pharmaceuticals ETF (XPH) a Strong ETF Right Now?

Smart Beta ETF report for XPH